DE60117561D1 - Verbesserte replikation von hcv rna - Google Patents

Verbesserte replikation von hcv rna

Info

Publication number
DE60117561D1
DE60117561D1 DE60117561T DE60117561T DE60117561D1 DE 60117561 D1 DE60117561 D1 DE 60117561D1 DE 60117561 T DE60117561 T DE 60117561T DE 60117561 T DE60117561 T DE 60117561T DE 60117561 D1 DE60117561 D1 DE 60117561D1
Authority
DE
Germany
Prior art keywords
hcv rna
provides methods
improved replication
cells
sub
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60117561T
Other languages
English (en)
Other versions
DE60117561T2 (de
Inventor
Hui-Hua Lu
Mark Selby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of DE60117561D1 publication Critical patent/DE60117561D1/de
Publication of DE60117561T2 publication Critical patent/DE60117561T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/69—Increasing the copy number of the vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DE60117561T 2000-08-04 2001-08-03 Verbesserte replikation von hcv rna Expired - Lifetime DE60117561T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22324400P 2000-08-04 2000-08-04
US223244P 2000-08-04
PCT/US2001/024276 WO2002012477A2 (en) 2000-08-04 2001-08-03 Enhanced replication of hcv rna

Publications (2)

Publication Number Publication Date
DE60117561D1 true DE60117561D1 (de) 2006-04-27
DE60117561T2 DE60117561T2 (de) 2007-01-11

Family

ID=22835673

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60117561T Expired - Lifetime DE60117561T2 (de) 2000-08-04 2001-08-03 Verbesserte replikation von hcv rna

Country Status (7)

Country Link
US (2) US6660471B2 (de)
EP (1) EP1320583B1 (de)
AT (1) ATE318893T1 (de)
AU (1) AU2001278139A1 (de)
CA (1) CA2416633C (de)
DE (1) DE60117561T2 (de)
WO (1) WO2002012477A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2050822B1 (de) * 2001-01-23 2013-07-31 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis C-Virus-Replicone und repliconerweiterte Zellen
EP1490389A4 (de) * 2002-04-03 2006-08-09 Smithkline Beecham Corp Subgenomische replicons des hepatitis-c-virus
US9945842B2 (en) 2010-09-03 2018-04-17 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840565A (en) * 1995-08-22 1998-11-24 The Regents Of The University Of California Methods for enhancing the production of viral vaccines in PKR-deficient cell culture
US6740519B1 (en) * 1997-11-03 2004-05-25 Mount Sinai School Of Medicine Immortalized, homozygous stat1-deficient mammalian cell lines and their uses

Also Published As

Publication number Publication date
US20020142455A1 (en) 2002-10-03
ATE318893T1 (de) 2006-03-15
US7183107B2 (en) 2007-02-27
WO2002012477A3 (en) 2003-04-10
US20040076612A1 (en) 2004-04-22
DE60117561T2 (de) 2007-01-11
EP1320583A2 (de) 2003-06-25
EP1320583B1 (de) 2006-03-01
US6660471B2 (en) 2003-12-09
CA2416633A1 (en) 2002-02-14
WO2002012477A2 (en) 2002-02-14
AU2001278139A1 (en) 2002-02-18
CA2416633C (en) 2013-04-30

Similar Documents

Publication Publication Date Title
ATE355380T1 (de) Methode zur selektiven inaktivierung der viralen replication
NO20081999L (no) Forbindelser og fremgangsmater for inhibering av hepatitt C viral replikasjon
DE69942708D1 (de) Virus enthaltende Zusammensetzungen und Methoden zur Konzentration von Viruspräparaten
DE50214416D1 (de) Vermehrung von viren in zellkultur
EA200900288A1 (ru) Вакцина
HUP0302957A2 (hu) Hepatitis C vírus alkil- és aril-alanin P2 csoportokat tartalmazó makrociklusos NS-3 szerin proteáz inhibitorai
NO20056074L (no) Hoy titer rekombinante influensavira til vaksiner og genterapi
DK1021547T3 (da) Vaccineformuleringer indeholdende papillomviruskapsomer og fremgangsmåder til anvendelse heraf
BRPI0412845A (pt) herpes-vìrus, uso de um vìrus, composição farmacêutica, e, método de tratamento de um tumor em um indivìduo em necessidade do mesmo
DE3486160T2 (de) Modifizierte lebende Pseudo-Rabies-Viren, diese enthaltende Impfstoffe gegen Pseudo-Rabies, Verfahren zur Herstellung und Verfahren zur Verwendung derselben.
EA200500584A1 (ru) Нуклеозидные производные для лечения инфекционных заболеваний, вызванных вирусом гепатита c
DK0698216T4 (da) Fremgangsmåder til typebestemmelse af hepatitis-C-virus og anvendte reagenser heri
DK0864646T3 (da) Fremgangsmåde til inaktivering af kappevira
NO20011162L (no) Fremgangsmåter og preparater for modulering av interaksjonen mellom APJ-reseptoren og HIV-viruset
EA200001193A1 (ru) 2-фенил-1-[4-(2-аминоэтокси)бензил]индол в комбинации с эстрогенами
ATE241994T1 (de) Hsv-mutant-1716 zur behandlung von mesotheliomen
ATE365206T1 (de) Verfahren zur entwicklung von einem hiv impfstoff
BR0108499A (pt) Agente terapêutico para hepatite c
DE69933121D1 (de) Methode, reagent und testsatz zur typisierung des genoms von papillomavirus
PT1242119E (pt) Combinacoes para o tratamento de infeccoes por virus adn incluindo um diuretico de ansa e um glicosido cardiotonico
DE60117561D1 (de) Verbesserte replikation von hcv rna
DK0906443T3 (da) Generering af replikerende molekyler in vivo
ATE337309T1 (de) Pyranon- und pyrandioninhibitoren der rna- abhängigen rna-polymerase des hepatitis-c-virus
DE69523055D1 (de) T-zellen stimulierendes protein von pestivirus
TR200201954T2 (tr) Viral hastalıklar için tıbbi maddeler.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US